首页> 外文会议>Bioengineering and Translational Medicine Conference >Utilizing Oxygen-Inhibited Photopolymerization to Control Size of Multimodal.PEGDA Hydrogel Nanoparticles for Cancer Therapeutics
【24h】

Utilizing Oxygen-Inhibited Photopolymerization to Control Size of Multimodal.PEGDA Hydrogel Nanoparticles for Cancer Therapeutics

机译:利用氧气抑制的光聚合以控制癌症治疗剂的多模式.PEGDA水凝胶纳米粒子的尺寸

获取原文

摘要

Cancer is a class of diseases characterized by hyperproliferative cell growth.Although there are many treatment options for cancer,it has been shown that the use of various modalities at the same time is a more effective treatment than sequentially applying the same modalities.Combining chemotherapy and immunotherapy agents in a nanoparticle equipped with targeting abilities has been shown to facilitate the elimination of cancerous tumors without the need of invasive surgery.Poly(ethylene glycol)diacrylate(PEGDA)hydrogel nanoparticles are of particular interest because of their biocompatibility,non-immunogenity,resistance to protein adsorption,and adjustable mechanical and chemical properties.One of the advantages of PEGDA includes its ability to be photopolymerized,which,consequently,provides increased spatial and temporal control over the hydrogel formation process.
机译:癌症是一类以过度增殖细胞生长为特征的疾病。虽然存在许多癌症的治疗方案,但已经表明同时使用各种方式是更有效的处理,而不是顺序应用相同的模态化疗和已经显示出纳米颗粒中的免疫疗法在纳米粒子中,已经显示出促进消除癌症的癌症,而不需要侵袭性手术。聚(乙二醇)二丙烯酸酯(PEGDA)水凝胶纳米颗粒由于其生物相容性,非免疫原性而特别感兴趣,抗蛋白质吸附和可调节的机械和化学性质。PEGDA的优点包括其光聚合的能力,因此,因此,在水凝胶形成过程中提供增加的空间和时间控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号